Windtree Therapeutics Inc  

(Public, NASDAQ:WINT)   Watch this stock  
Find more results for Mary M. Roberts
-0.01 (-0.56%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.73 - 1.83
52 week 1.42 - 7.93
Open 1.73
Vol / Avg. 8,063.00/28,714.00
Mkt cap 14.25M
P/E     -
Div/yield     -
EPS -7.66
Shares 8.23M
Beta 1.68
Inst. own 43%
Aug 8, 2016
Q2 2016 Windtree Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2016
Q1 2016 Windtree Therapeutics Inc Earnings Release
May 12, 2016
Q1 2016 Windtree Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -18534.67% -5589.67%
Operating margin -18589.33% -5227.15%
EBITD margin - -3963.73%
Return on average assets -141.00% -120.10%
Return on average equity -3390.50% -401.75%
Employees 58 -
CDP Score - -


2600 Kelly Rd Ste 100
WARRINGTON, PA 18976-3652
United States - Map
+1-215-4889300 (Phone)
+1-215-4889301 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Officers and directors

John R. Leone Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Craig Fraser President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
John A. Tattory Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Mary B. Templeton Esq. Senior Vice President, General Counsel and Corporate Secretary
Age: 68
Bio & Compensation  - Reuters
Kathryn A. Cole Senior Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
Steven G. Simonson M.D. Senior Vice President and Chief Development Officer
Age: 56
Bio & Compensation  - Reuters
William C. Roberts Vice President - Investor Relations and Corporate Communications
Age: 45
Bio & Compensation  - Reuters
Michael L. Magee Vice President - Technical Operations
Age: 54
Bio & Compensation  - Reuters
Joseph M. Mahady Independent Director
Age: 62
Bio & Compensation  - Reuters
Bruce A. Peacock Independent Director
Age: 64
Bio & Compensation  - Reuters